

Patent Application Attorney Docket No. PC25421A

Thereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this day of February 2005.

Signature of person mailing)

ONI ORA

(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Coe, et al.

APPLICATION NO.: 10/791,984 : Examiner: Not Yet Assigned

FILING DATE: March 3, 2004 : Group Art Unit: 1614

TITLE: A PHARMACEUTICAL COMPOSITION:

FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE

**WEIGHT LOSS** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date:

Respectfully submitted,

A. David Joran

Attorney for Applicant(s)

Reg. No. 37,858

Pfizer Inc

(212)573 -3381

Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 MAR 0 4 2005

ORMATION DISCLOSURE CITATION						ATT	ATTY. DOCKET NO. PC25421A SERIAL NO. 10/791,984								
(Use several sheets if necessary)							APPLICANT Coe, et al.								
							NG DAT		GROUP 1614						
						U.S. P	ATENT	DOCU						_	
CAMINER INITIAL				DOC	JMENT NUM	BER	· <del></del>		DATE	NAME	CLASS	SUBCLASS	FILING IF APPROF	PRI	
			Ì												
					FC	REIG	N PATE	NT DO	UMENTS						
			DOX	CUMENT NU	IMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	LA	
						\ 							YES		
		1	1	6	9	9	7	0	12/05/01	EP					
		9	8	1	8	7	9	8	05/07/98	wo					
		9	9	3	5	1	3	1	07/15/99	wo					
		9	9	5	5	6	8	0	11/04/99	wo					
		8	1	5	8	4	5	0	08/19/04	wo			ł		
		3	0	2	7	0	7	6	04/03/03	wo					
	0			2	8	3	4	5	04/11/02	wo					
	-	6	2			6	3	4	09/07/01	wo				-	
		0	1 1	6	4	4	4	1	07/30/98	wo				-	
	-	9	8	3	2					wo				_	
	-	0	1	3	2	6	6	3	05/10/01					-	
	0	4	0	3	7	8	2	3	05/06/04	wo_		<del> </del>		-	
	0	4	0	6	9	8	3	7	08/19/04	wo		<u> </u>	<del> </del>	-	
	0	4	0	6	9	8	3	6	08/19/04	wo			-		
	0	4	0	3	5	5	6	6	04/29/04	wo			-	_	
	0	4	0	- 5	2	8	6	4	06/24/04	wo					
<del></del>			OTHE	R DOC	UMENT	S (Incl	uding Au	ıthor, Ti	tle, Date, l	Pertinent Pag	ges, Etc.)			=	
10.		Le, e Beha	Le, et al.; Alcohol Consumption by C57BL/6, BALB/c, and DBA/2 Mice in a Limited Access Paradigm; Pharmacol. Biochem. A Behavior; 47; 375-378 (1994).												
11.		Inter	national S	earch Re	port, PCT	IB2004/	001415, C	ecember	6, 2004					_	
XAMIN	JER							DATE	CONSIDERE	D					
>\-\IVIII\								,							
					citation is in c				-			20-62		-	